On September 6, 2022 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported that new data from its portfolio of blood tests will be presented at the 2022 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress, September 9-13 in Paris, France (Press release, Guardant Health, SEP 6, 2022, View Source [SID1234619091]). Among the seven abstracts are an oral presentation and posters highlighting the use of Guardant Health’s blood tests and real-world evidence dataset to advance cancer therapy trials, predict and monitor patient response to therapy, and identify genomic mechanisms of acquired resistance to cancer therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to sharing new data at ESMO (Free ESMO Whitepaper) demonstrating the utility of our blood tests to increase the understanding of potential new biomarker targets and the mechanisms of therapy resistance in patients with cancer," said Helmy Eltoukhy, Guardant Health co-CEO. "The data from retrospective and real-world analyses show how comprehensive genomic profiling tests provide critical insights at every step of a patient’s treatment journey, and ultimately contribute to the development of more effective therapies and improved patient outcomes."
Full List of Guardant Health Presentations
GuardantOMNI
Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study (Oral Presentation 316O)
Interim biomarker analysis of a phase 1b/2 study of anti-TIGIT etigilimab (MPH313) and nivolumab in subjects with select locally advanced or metastatic solid tumors (ACTIVATE) (Presentation 111P)
Clinical potential of circulating tumor DNA (ctDNA)–based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response to first-line (1L) chemoimmunotherapy in advanced squamous non-small cell lung cancer (sqNSCLC) (Presentation 1092P)
Early decreases in KRAS mutant allele frequency (MAF) predicts clinical benefit to the PLK1 inhibitor onvansertib in combination with FOLFIRI/bev in 2L treatment of metastatic colorectal carcinoma (mCRC) (Presentation 397P)
The PLK1 inhibitor onvansertib overcomes irinotecan resistance in RAS-mutated (mRAS) metastatic colorectal cancer (mCRC) in vivo and in patients (pts) (Presentation 366P)
Guardant360
Resistance mechanisms to lorlatinib or crizotinib in treatment-naive patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) (Presentation 1008P)
GuardantINFORM
Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations (Presentation 1407P)
The full abstracts are available on the official ESMO (Free ESMO Whitepaper) 2022 website.